Nov 18, 2024 8:45am EST Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Oct 31, 2024 9:15am EDT Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
Oct 30, 2024 9:15am EDT Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Oct 07, 2024 7:05am EDT Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
Aug 01, 2024 9:41am EDT Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Jul 23, 2024 9:15am EDT Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
May 22, 2024 1:30pm EDT Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 19, 2024 8:53pm EDT Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
